A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group
- PMID: 9686768
- DOI: 10.1002/mds.870130406
A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group
Abstract
Tolcapone is a potent, reversible catechol-O-methyltransferase (COMT) inhibitor with both peripheral and central activity. It has been demonstrated to improve motor function and allow levodopa dose reductions in Parkinson's disease (PD) patients who are experiencing either a stable response or motor fluctuations while on levodopa/dopa decarboxylase inhibitor therapy. Because striatal dopamine is metabolized by COMT and monoamine oxidase (MAO), central COMT inhibition alone or in combination with MAO inhibition might provide symptomatic benefit for patients not receiving levodopa. We conducted a pilot study to evaluate the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in early untreated PD patients. Patients were randomized to receive 200 mg tolcapone three times a day or placebo for the 8 weeks of the study. Open-label oral selegiline (5 mg in the morning and midday) was administered to all patients during the second 4 weeks of the study. There was no difference between treatment groups according to the investigator's assessment of tolerability at week 4. Ninety-five percent of tolcapone-treated patients and 98% of placebo-treated patients experienced excellent or good tolerability during the first 4 weeks (95% confidence interval [CI]: -10.3, 5.7; p = 0.57). A decrease in tolerability occurred in the tolcapone group during the second 4 weeks of the study following the addition of selegiline. The most commonly reported side effects were diarrhea (31% tolcapone, 7% placebo), nausea (21% tolcapone, 2% placebo), urine discoloration (12% tolcapone, 0% placebo), dizziness (12% tolcapone, 5% placebo), headaches (12% tolcapone, 10% placebo), and abdominal pain (10% tolcapone, 5% placebo). We did not identify symptomatic benefit associated with tolcapone alone or in combination with oral selegiline in this group of otherwise untreated PD patients.
Similar articles
-
Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.Int Rev Neurobiol. 2010;95:207-25. doi: 10.1016/B978-0-12-381326-8.00009-0. Int Rev Neurobiol. 2010. PMID: 21095464 Review.
-
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.Clin Ther. 2007 Sep;29(9):1825-49. doi: 10.1016/j.clinthera.2007.09.021. Clin Ther. 2007. PMID: 18035186 Review.
-
Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group.Mov Disord. 1999 Jan;14(1):38-44. Mov Disord. 1999. PMID: 9918342 Clinical Trial.
-
Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.Mov Disord. 1997 Jul;12(4):497-505. doi: 10.1002/mds.870120404. Mov Disord. 1997. PMID: 9251066 Clinical Trial.
-
Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.Mov Disord. 1995 May;10(3):349-51. doi: 10.1002/mds.870100321. Mov Disord. 1995. PMID: 7651456 Clinical Trial.
Cited by
-
Effects of pharmacological and genetic regulation of COMT activity in alcohol use disorder: a randomized, placebo-controlled trial of tolcapone.Neuropsychopharmacology. 2022 Oct;47(11):1953-1960. doi: 10.1038/s41386-022-01335-z. Epub 2022 May 6. Neuropsychopharmacology. 2022. PMID: 35523943 Free PMC article. Clinical Trial.
-
Experimental Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of the Evidence.J Exp Pharmacol. 2021 Mar 29;13:397-408. doi: 10.2147/JEP.S267032. eCollection 2021. J Exp Pharmacol. 2021. PMID: 33824605 Free PMC article. Review.
-
Slurring of Speech and Lip Paresthesia: Symptoms of Levodopa End of Dose Wearing Off in Parkinson's Disease.Cureus. 2018 Jul 16;10(7):e2986. doi: 10.7759/cureus.2986. Cureus. 2018. PMID: 30237947 Free PMC article.
-
Catechol-O-methyltransferase inhibitors in Parkinson's disease.Drugs. 2015 Feb;75(2):157-74. doi: 10.1007/s40265-014-0343-0. Drugs. 2015. PMID: 25559423 Review.
-
Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients.J Neural Transm (Vienna). 2015 Jan;122(1):43-58. doi: 10.1007/s00702-014-1290-3. Epub 2014 Aug 17. J Neural Transm (Vienna). 2015. PMID: 25129258
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous